ReviewCureus2024
Examination of Lipoprotein and Lipid Levels of Adult Patients With Atherosclerosis, Myocardial Infarction, and Stroke: A Narrative Review.
Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Iron-Sulfur Cluster Targeting: A Novel Perspective for Treating Alcohol-Related Lipid Metabolic Diseases.Journal of biochemical and molecular toxicology · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The literature revealed correlations between high-density lipoprotein (HDL), low-density lipoprotein (LDL), and very low-density lipoprotein (VLDL) and vaso-occlusive disease. Specifically, positive linear relationships exist between LDL and VLDL and the development of vaso-occlusive disease. Alternatively, a U-shaped relationship between HDL and vaso-occlusive disease exists where both low and high levels of HDL increase the risk of developing conditions such as myocardial infarction and atherosclerosis. These results align with the National Institute of Health's lipoprotein targets. Recent literature postulates that the adverse effects associated with lipoproteins may be attributable to commonalities between the structures of HDL, LDL, and VLDL, such as apolipoprotein subunits and molecular sizes that are not commonly analyzed in clinical lab tests. Nonetheless, additional research remains ongoing to further understand the role of lipoproteins in atherogenesis and vaso-occlusive disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.